CoChat

Escitalopram Continuation Treatment Prevents Relapse of Depressive Episodes

Rapaport, Mark Hyman, Bose, Anjana, Zheng, Hongjie · 2004 · The Journal of Clinical Psychiatry

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Abstract

Background Current guidelines for antidepressant use recommend 4 to 6 months of continuation treatment to prevent relapse of depression following symptom resolution. This study evaluates the efficacy and safety of continuation escitalopram treatment. Method Outpatients diagnosed with DSM-IV major depressive disorder (male or female, aged 18 to 81 years) who had completed 8 weeks of randomized double-blind treatment with escitalopram, citalopram, or placebo entered an 8-week flexible-dose, open-label phase in which all patients received escitalopram (10-20 mg/day). This study was initiated November 3, 1999, and completed April 5, 2001. Patients who met responder criteria (score of or = 22 or discontinuation due to an insufficient therapeutic response) from the start of the double-blind treatment phase. Results A total of 502 patients received open-label escitalopram treatment and had at least 1 MADRS assessment. A total of 274 evaluable subjects entered the double-blind treatment phase; 93 received placebo and 181 received escitalopram. Time to depression relapse was significantly longer (p =.013) and the cumulative rate of relapse was significantly lower in patients who received escitalopram (26% escitalopram vs. 40% placebo; hazard ratio = 0.56; p =.01). Escitalopram-treated subjects had significantly lower depression ratings than those of placebo-treated patients. Escitalopram continuation treatment was safe and well tolerated. Discontinuation rates due to adverse events we…

Overview

Integrity signals

Registry

Crossref · 10.4088/jcp.v65n0107

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 24 references

Cited by

See all 121

Metadata

Authors
Rapaport, M. H., Bose, A., & Zheng, H.
Affiliations
Cedars-Sinai Medical Center (US)
Venue
The Journal of Clinical Psychiatry
Published
2004-01-15
Volume
65
Issue
1
Pages
44-49
ISSN
0160-6689 (ISSN-L)
OpenAlex
W2077027462
Cited by
121
References
24
Citations by year
2026: 1 · 2025: 3 · 2024: 1 · 2023: 1 · 2022: 4 · 2021: 3 · 2020: 3 · 2019: 2 · 2018: 2 · 2017: 1 · 2016: 1 · 2015: 6 · 2014: 5 · 2013: 1 · 2012: 3
FWCI
11.56
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
Keywords
escitalopram, continuation treatment, relapse prevention, major depressive disorder, antidepressant efficacy, citalopram, open-label extension, adverse events, treatment safety
MeSH terms
Administration, Oral, Adolescent, Adult, Aged, Aged, 80 and over, Depressive Disorder, Double-Blind Method, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Placebos, Prognosis, Psychiatric Status Rating Scales, Recurrence, Citalopram, Treatment Outcome, Antidepressive Agents, Second-Generation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Escitalopram Continuation Treatment Prevents Relapse of Depressive Episodes. https://app.cochat.ai/papers/10.4088/jcp.v65n0107
The paper
Rapaport, M. H., Bose, A., & Zheng, H. (2004). Escitalopram Continuation Treatment Prevents Relapse of Depressive Episodes. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.v65n0107

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.